Status:
TERMINATED
Assessment and Tracking of Long-term Alefacept Safety
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
Subjects exposed to alefacept are to be enrolled. Subjects will be contacted every 6 months to gather general health information.
Detailed Description
There are no study-mandated tests, visits or clinical interventions after the 1st (enrolling) visit. After the patient is enrolled in the study, they will be contacted every 6 months to complete struc...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Psoriasis patients who are prescribed alefacept consistent with product labeling are eligible for enrollment.
Exclusion
Key Trial Info
Start Date :
June 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
1897 Patients enrolled
Trial Details
Trial ID
NCT00454701
Start Date
June 1 2003
End Date
February 1 2012
Last Update
December 11 2013
Active Locations (268)
Enter a location and click search to find clinical trials sorted by distance.
1
Total Skin and Beauty Dermatology Center
Birmingham, Alabama, United States, 35205
2
Janet Cash
Birmingham, Alabama, United States, 35213
3
Bay Shore Dermatology & Laser Surgery Center
Fairhope, Alabama, United States, 36532
4
Eric Baum
Gadsden, Alabama, United States, 35901